Bridgeway Capital Management’s Coherus Oncology CHRS Stock Holding History

Bridgeway Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$547K	Sell	391,000 -50,000	-11%	-$81.6K	0.01%	828
2026 Q1	$745K	Hold	441,000	–	–	0.02%	758
2025 Q4	$626K	Buy	441,000 +186,000	+73%	+$271K	0.01%	782
2025 Q3	$418K	Buy	255,000 +112,000	+78%	+$125K	0.01%	840
2025 Q2	$105K	Hold	143,000	–	–	﹤0.01%	1065
2025 Q1	$115K	Sell	143,000 -60,000	-30%	-$69.1K	﹤0.01%	1010
2024 Q4	$280K	Sell	203,000 -109,700	-35%	-$123K	0.01%	939
2024 Q3	$325K	Buy	312,700 +69,700	+29%	+$95.6K	0.01%	962
2024 Q2	$420K	Buy	+243,000	New	+$489K	0.01%	896

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Bridgeway Capital Management's CHRS Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Coherus Oncology (CHRS) stake by 11% in Q2 2026, selling an estimated $81.6K and leaving 391,000 shares worth $547K. The position accounts for 0.01% of the portfolio, ranked #828.

Bridgeway Capital Management first reported a position in CHRS in Q2 2024 and has held it in 9 quarters since. The position peaked at $745K in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Bridgeway Capital Management held 391,000 shares of Coherus Oncology worth $547K as of Q2 2026.
Bridgeway Capital Management sold 50,000 Coherus Oncology shares in Q2 2026, an estimated $81.6K.
Coherus Oncology made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #828 holding.
Bridgeway Capital Management first reported a position in Coherus Oncology in Q2 2024 and has held it in 9 quarters since.
Bridgeway Capital Management's Coherus Oncology position peaked at $745K in Q1 2026.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.